Enquiry
[email protected]
[email protected]
| We established a quick response research team to monitor the impacts of global pandemic COVID19 on this market to keep our clients informed about latest data and changing strategies. The report will incorporate these insight and data factors. | × |
|---|
Global Orphan Drugs Market is expected to reach the valuation of USD 181.21 billion by 2025 and register a CAGR of 11.56% during the forecast period, 2017-2025. Moreover, pharma companies focus on the conditions that affect much larger pool of patient. However, orphan drugs that tackle rare diseases strike much smaller numbers of patients globally, incentives are introduced to motivate pharma companies to perform the lengthy and costly work of developing the required orphan drugs. According to our analysis the mean cost per patient for orphan drugs was around USD 150,000 per patient in 2016, which is four times that of the cost of non-orphan drugs. The most expensive drug (Soliris) actually weighed in at a cost of around USD 500,000 per year.
The report covers the present ground scenario and the future growth prospects of the Orphan Drugs market for 2017-2025 along with new product launches, clinical trials, number of drugs registered, waiting for approval, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. We calculated the market size and revenue share on the basis of revenue generated from major players across the globe. The market forecast is done on the basis of orphan drugs launched in various areas and their market presence across the globe.
Market exclusivity for authorization of marketing orphan drugs is reserved for companies that gain approval. For instance, in Europe, companies are granted 10 years of market exclusivity from the time of approval, which is the same for the Japan market. However, in the US, this exclusivity is a little less than seven years.
Most of the vendors which are entering the orphan and rare dermatology market over the forecast period are smaller companies with more specialized product portfolios. However, across orphan and rare dermatological diseases, there is a strong need for innovation and development of effective disease-modifying drugs as pipeline of 262 active products for orphan and rare dermatology diseases, considering how rare most of the disorders are.
Celgene is expected to be the leading company in the orphan drug market in 2024 with sales of USD 18.5 billion; all other companies like Johnson & Johnson, Novartis, Roche, Merck & Co., Bristol-Myers Squibb, Shire, AbbVie, Sanofi, Alexion Pharmaceuticals ranked in the top are expected to achieve sales ranging from USD 7.1 billion to USD 15 billion. Except than Alexion Pharmaceuticals, these companies are anticipated for 60% of the orphan drug (in the oncology therapy area) sales by 2024.
.jpg)
Global Orphan Drugs Competitor Share Analysis, On the basis of Sales in 2017
On The Basis of Therapy Category
Blood, and central nervous system are expected to be the leading therapy categories in the non-oncology space, together capturing about 44.03% of this market by 2024. Top 10 companies in oncology orphan drug market are the major pharmaceutical companies; among which Celgene is ranked on first position with sales of USD 17.18 billion.
On The Basis of Drugs
On The Basis of Geography
|
Product Analysis |
|
|
Epidemiology Data |
|
|
Manufacturer Analysis |
|
|
Brand/Product Perception Matrix |
|
|
Alternative Products: Impact analysis |
It is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters like patient dynamics (Patient pool, epidemiology of disease, preference towards orphan drugs) and Macroeconomic indicators (investment rate and FDA regulations). |
A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements
OR Call Us:+1-646-568-7747